ArticleFrontiers in pharmacology2025
Simvastatin impairs fracture healing under ischemic conditions.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients suffering from fractures are often required to take simvastatin during the bone healing phase due to co-morbidities. However, the impact of simvastatin on fracture healing under ischemic conditions remains unclear so far. Therefore, we analyzed in this study the effect of simvastatin on fracture healing in an established murine ischemia model. Mild ischemia of the right hind limb and a femoral fracture was induced in CD-1 mice. After stabilization of the fracture by an intramedullary screw, the animals received either 30 mg/kg body weight simvastatin per os daily or an equivalent amount of vehicle (control). Bone healing was analyzed by biomechanical as well as radiological, histomorphometric and Western blot analyses 2 and 5 weeks postoperatively. The fractured femurs of both groups exhibited a delayed healing throughout the study period. Bone formation, as assessed by micro-computed tomography, was significantly reduced in the callus tissue of femurs in simvastatin-treated animals compared to controls. Moreover, these femurs showed histomorphometric signs of ongoing healing and a tendency towards less bone tissue at 2 weeks after surgery. Western blot analyses revealed an increased expression of CD31 and phosphoinositide-3-kinase (PI3K) after simvastatin treatment, whereas the expression of bone morphogenetic protein (BMP)-2 was significantly decreased. In conclusion, these results demonstrate that simvastatin impairs fracture healing under challenging ischemic conditions. This effect is most likely caused by an imbalance of angiogenesis and osteogenesis in the callus tissue. These findings indicate that the use of simvastatin during fracture healing under ischemic conditions warrants careful reconsideration in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.